Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 years

• John E. Harris,
• Amit G. Pandya,
• Mark Lebwohl,
• Iltefat H. Hamzavi,
• Pearl Grimes,
• Alice B. Gottlieb,
• Howard L. Sofen,
• Angela Y. Moore,
• Mingyue Wang,
• Deanna Kornacki,
• Kathleen Butler,
• David Rosmarin

Affiliations

John E. Harris

University of Massachusetts Chan Medical School Worcester Massachusetts USA

Amit G. Pandya

Palo Alto Foundation Medical Group Sunnyvale California USA

Mark Lebwohl

Icahn School of Medicine at Mount Sinai New York New York USA

Iltefat H. Hamzavi

Henry Ford Medical Center Detroit Michigan USA

Pearl Grimes

The Vitiligo & Pigmentation Institute of Southern California Los Angeles California USA

Alice B. Gottlieb

Icahn School of Medicine at Mount Sinai New York New York USA

Howard L. Sofen

David Geffen UCLA School of Medicine Los Angeles California USA

Angela Y. Moore

Arlington Research Center Arlington Texas USA

Mingyue Wang

Incyte Corporation Wilmington Delaware USA

Deanna Kornacki

Incyte Corporation Wilmington Delaware USA

Kathleen Butler

Incyte Corporation Wilmington Delaware USA

David Rosmarin

Indiana University School of Medicine Indianapolis Indiana USA